Viral Hepatitis Pharm Flashcards
1
Q
Entecavir
A
- HBV TREATMENT
- NRTI
- Do NOT use for patients with HIV
- RISK of LATCITC ACIDOSIS and hepatomegaly
2
Q
Tenofovir disoproxil
A
- HBV and HIV TREATMENT
- NRTI
- RISK of LACTIC ACIDOSIS, RENAL FAILURE(Fanconi syndrome), and hepatomegaly with steatosis
3
Q
Adefovir
A
- HBV TREATMENT
- NRTI
- Risk of NEPHROTOXICITY (requires renal monitoring)
4
Q
Lamivudine
A
- HBV and HIV TREATMENT
- NRTI
- RISK of LACTIC ACIDOSIS, PANCREATITIS, and severe hepatomegaly
5
Q
Telbivudine
A
- HBV TREATMENT
- NRTI
- Risk of LACTIC ACIDOSIS and severe hepatomegaly with steatosis
- do not combine with PEG Interferon Alfa-2a due to risk of peripheral neuropathy
6
Q
PEG Interferon Alfa-2a
A
-CHRONIC HBV AND HCV TREATMENT
-activates innate antiviral response
-only indicated for HCV if the patient has not been treated with ifn-α before
RISK of RIBAVIRIN ASSOCIATED EFFECTS
7
Q
PEG Interferon Alfa-2b
A
- HCV TREATMENT
- activates innate antiviral response
- Can cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.
8
Q
Elbasvir/Grazoprevir
A
- HCV TREATMENT
- NS5A inhibitor (elbasvir)
- NS3/4A inhibitor (grazoprevir)
- Risk of ALT ELEVATIONS
- don’t use with CYP inhibitors
9
Q
Ledipasvir/Sofosbuvir
A
- HCV TREATMENT
- NS5A inhibitor (ledipasvir)
- NS5B polymerase inhibitor (sofosbuvir)
- must be combined with ribavirin\
- don’t combine with other drugs containing sofosbuvir
- don’t use with CYP inhibitors
10
Q
Velpatasvir/Sofosbuvir
A
- HCV TREATMENT (with or w/o cirrhosis)
- NS5A inhibitor (velpatasvir)
- NS5B polymerase inhibitor (sofosbuvir)
- must be combined with ribavirin
- don’t use with CYP inhibitors
11
Q
Ribavirin
A
- HCV TREATMENT
- RISK of BIRTH DEFECTS AND FETAL DEATH
- combined with Interferon alfa-2a
12
Q
Boceprevir
A
- HCV TREATMENT
- NS3/4A protease inhibitor
- used in combination with peginterferon alfa and ribavirin
